Press Releases Recordati

Equities

REC

IT0003828271

Pharmaceuticals

Market Closed - Borsa Italiana Other stock markets 12:45:00 2026-03-11 pm EDT			5-day change	1st Jan Change
46.22 ^EUR	-2.65%		-3.63%	-4.78%

Mar. 10	Recordati acquires 114,393 treasury shares for over EUR5 million	AN
Mar. 06	DIARY - Italy to April 30	RE

Press Releases

Feb. 17	RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%	GL
Feb. 17	RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE 11.8%, EBITDA 14.5%, ADJUSTED NET INCOME 14.5%	PU
Jan. 29	RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA	GL
Jan. 14	Recordati : 14 January 2026 - J.P. Morgan Healthcare Conference Presentation	PU
Nov. 14	Recordati : First nine months 2025	PU
Nov. 11	RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION	GL
Nov. 11	Recordati : Directors' report on the distribution of an interim dividend and interim financial statements at 30 June 2025	PU
25-10-23	RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER	GL
25-10-21	Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology	GL
25-07-31	RECORDATI: PUBLICATION OF THE MINUTES OF THE BOARD OF DIRECTORS’ MEETING HELD ON 29 JULY 2025	PU
25-07-31	Recordati : First Half 2025	PU
25-07-31	RECORDATI: PUBLICATION OF THE INTERIM REPORT FIRST HALF (AS AT 30.06.2025)	PU
25-07-29	RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%	GL
25-06-24	RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE	GL
25-05-12	Recordati : First Quarter Report 2025	PU
25-05-08	RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%	GL
25-04-30	RECORDATI: SUMMARY REPORT OF THE VOTES – ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2025	PU
25-04-30	Recordati : 30 April 2025 - Summary report of the votes	PU
25-04-29	RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2024 FINANCIAL STATEMENTS AND THE DIVIDEND OF € 1.27 PER SHARE (+5.8% vs 2023). THE NEW BOARD OF DIRECTORS HAS BEEN APPOINTED	PU
25-04-28	RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION	GL
25-04-16	RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME	GL
25-03-28	Recordati : 28 March 2025 - Directors' Report on item 1 on the agenda – Financial statements approval and allocation of profit	PU
25-03-28	Recordati : 28 March 2025 - Report of the Board of Statutory Auditors to the Shareholders’ Meeting	PU
25-03-28	Recordati : 28 March 2024 - Financial Statements of Recordati S.p.A. at 31 December 2024 and related Report of the Auditing Firm	PU
25-03-28	Recordati : 28 March 2025 – Integrated Consolidated Financial Statements 2024 and related Reports of the Auditing Firm	PU